Sugi Predict

Sugi Predict / Compounds / SCHEMBL234634

SCHEMBL234634

SCHEMBL234634

CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.88
▸ NR5A2 O00482 1/20 0.88
▸ NR5A1 Q13285 1/20 0.88
▸ MAPT P10636 1/20 0.78
▸ ALDH1A1 P00352 1/20 0.78
▸ FABP3 P05413 1/20 0.70
▸ RECQL P46063 1/20 0.69
▸ ADRA1D P25100 1/20 0.59
▸ PTAFR P25105 1/20 0.59
▸ HTR1D P28221 1/20 0.59
▸ HTR2C P28335 1/20 0.59
▸ ADRA1B P35368 1/20 0.59
▸ DRD3 P35462 1/20 0.59
▸ TMEM97 Q5BJF2 1/20 0.59
▸ PRKCE Q02156 1/20 0.58
▸ PRKCQ Q04759 1/20 0.58
▸ PRKCD Q05655 1/20 0.58
▸ PRKCA P17252 1/20 0.58
▸ SELP P16109 1/20 0.57
▸ ENPP2 Q13822 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159882 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL15709161 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL178155 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL23188433 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL235532 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL25354838 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL416515 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL45162 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL22492184 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1
SCHEMBL1649042 1.00 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144803-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF EDEN OPHTHALMIC PTE LTD. (SG) 2026-05-28 — — US claimed
EP-4743094-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF Eden Ophthalmic Pte Ltd. (SG) 2026-05-20 — — EP claimed
WO-2026090590-A1 NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE Remedium Bio, Inc. (US) 2026-04-30 — — WO claimed
EP-4731002-A2 SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS Tenfold Technologies, LLC (US) 2026-04-29 — — EP claimed
EP-4695401-A1 SYNTHETIC CIRCUITS AND USES THEREOF Strand Therapeutics Inc. (US) 2026-02-18 — — EP claimed
WO-2025080945-A1 LIPID NANOPARTICLES CodeBridgeBio Inc. (US) 2025-04-17 — — WO claimed
WO-2025024704-A1 POLYNUCLEOTIDES COMPRISING A MICRO RNA DETARGETING SENSOR AND USES THEREOF STRAND THERAPEUTICS INC. (US) 2025-01-30 — — WO claimed
WO-2025024559-A1 RNA-BASED SYNTHETIC CIRCUIT FOR PRODUCING ENGINEERED IMMUNE CELLS FOR AN EXTRACORPOREAL CELL THERAPY STRAND THERAPEUTICS INC. (US) 2025-01-30 — — WO claimed
WO-2025015046-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF EDEN OPHTHALMIC PTE LTD. (SG) 2025-01-16 — — WO claimed
WO-2024263793-A2 SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS Tenfold Technologies, LLC (US) 2024-12-26 — — WO claimed
CN-114728078-A Extracellular vesicles linked to molecules and uses thereof 科迪亚克生物科学公司 2022-07-08 — — CN claimed
CN-109596748-B Method for detecting metabolites of gandi capsules for treating diabetic nephropathy patients 上海交通大学医学院附属新华医院 2022-03-04 — — CN claimed
US-20180344644-A1 IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF IKARIA THERAPEUTICS LLC 2018-12-06 — — US claimed
WO-2012052539-A1 NOVEL NEUTRAL (BIO)MATERIAL CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2012-04-26 — — WO claimed
EP-2444464-A1 Novel neutral (bio)material Centre National de la Recherche Scientifique (CNRS) (FR) 2012-04-25 — — EP claimed
US-20090191259-A1 Efficient liposomal encapsulation TRANSAVE, INC. (US) 2009-07-30 — — US claimed
EP-1478341-A4 EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES TRANSAVE INC (US) 2009-05-20 — — EP claimed
US-20060058249-A1 Efficient nucleic acid encapsulation into medium sized liposomes TRANSAVE, INC. 2006-03-16 — — US claimed
EP-1478341-A1 EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES Elan Pharmaceuticals, Inc. (US) 2004-11-24 — — EP claimed
WO-2003059322-A1 EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES ELAN PHARMACEUTICALS, INC. (US) 2003-07-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180344644-A1 IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF SGMS2, SGMS1, LIPA SMN1; SMN2 2605/4885NR5A2 1869/4885NR5A1 296/4885
US-20260144803-A1 LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF STARD3, STARD7, PHOSPHO1 SMN1; SMN2 3764/4885NR5A2 912/4885NR5A1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.